Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Globus MedicalBSP:G2ME34 26 EV-to-EBITDA is 0.91 as of Aug. 11, 2026, which is 96% below its 10-year median of 20.98. GuruFocus rates BSP:G2ME34 with a GF Score™ of 26/100 and a GF Value™ of R$58.52 (Modestly Undervalued). The stock has 5 warning signs investors should review. Among 516 Medical Devices & Instruments companies, Globus Medical ranks better than 61.43% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Globus Medical's enterprise value is R$4,587 Mil.
Globus Medical's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 was R$5,044 Mil. Therefore, Globus Medical's EV-to-EBITDA for today is 0.91.
The historical rank and industry rank for Globus Medical's EV-to-EBITDA or its related term are showing as below:
BSP:G2ME34'
s EV-to-EBITDA Range Over the Past 10 Years
Min: 8.82 Med: 20.98 Max: 36.91
Current: 0.95
During the past 13 years, the highest EV-to-EBITDA of Globus Medical was 36.91. The lowest was 8.82. And the median was 20.98.
BSP:G2ME34's EV-to-EBITDA is ranked better than 61.43% of 516
companies
in the Medical Devices & Instruments industry
Industry Median: 14.81
vs BSP:G2ME34: 0.95
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Globus Medical (BSP:G2ME34) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Globus Medical's PE Ratio (TTM) for today is calculated as:
Globus Medical's share price for today is R$52.00.
Globus Medical's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was R$20.682.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Globus Medical's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BSP:G2ME34 vs PODD, BRKR, GKOS: EV-to-EBITDA Comparison
For the Medical Devices subindustry, Globus Medical's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Globus Medical EV-to-EBITDA vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Globus Medical's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Globus Medical's EV-to-EBITDA falls into.
Globus Medical's current Enterprise Value is R$4,587 Mil.
Globus Medical's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was R$5,044 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Globus Medical (BSP:G2ME34) has a EV-to-EBITDA of 0.91 as of Aug. 11, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Globus Medical. This is 96% below median its historical median of 20.98. Over the past decade, Globus Medical's EV-to-EBITDA has ranged from 8.82 to 36.91. According to the industry distribution chart, Globus Medical ranks #199 out of 516 companies in the Medical Devices & Instruments industry, placing it in the top 38.6%.
Is Globus Medical's EV-to-EBITDA too high?
Globus Medical's current EV-to-EBITDA of 0.91 is 96% below median its 10-year median of 20.98. Over the past 10 years, this metric has ranged from a low of 8.82 to a high of 36.91. The Medical Devices & Instruments industry median EV-to-EBITDA is 14.81. Globus Medical's value of 0.91 is 93.9% below this industry median. Based on the distribution chart, Globus Medical ranks #199 out of 516 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Globus Medical has a GF Score™ of 26/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Globus Medical's EV-to-EBITDA compare to PODD and BRKR?
According to the Medical Devices & Instruments industry distribution chart, Globus Medical ranks #199 out of 516 companies for EV-to-EBITDA. This puts Globus Medical in the upper half of its industry. The industry median EV-to-EBITDA is 14.81. Globus Medical's value of 0.91 is 93.9% below this benchmark. Historically, Globus Medical's own EV-to-EBITDA has ranged from 8.82 to 36.91 over the past decade. While the company's 10-year median is 20.98 vs. the industry median of 14.81, Globus Medical has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Medical Devices & Instruments company?
The median EV-to-EBITDA among Medical Devices & Instruments companies is 14.81, based on 516 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Globus Medical's current EV-to-EBITDA of 0.91 is 93.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Globus Medical. For the Medical Devices & Instruments industry, the median EV-to-EBITDA is 14.81 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Globus Medical's current EV-to-EBITDA is 0.91, which is 96% below median its own 10-year median of 20.98. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Globus Medical stock overvalued right now?
Based on GuruFocus' analysis, Globus Medical (BSP:G2ME34) is currently considered Modestly Undervalued. The stock's GF Value™ is R$58.52, compared to a current price of R$52.00 — trading 11.1% below its estimated fair value. The current EV-to-EBITDA is 0.91, which is 96% below median its 10-year median of 20.98 and 93.9% below the Medical Devices & Instruments industry median of 14.81. Globus Medical's overall GF Score™ is 26/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Globus Medical (BSP:G2ME34), the current EV-to-EBITDA is 0.91 as of Aug. 11, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Globus Medical (BSP:G2ME34) Overvalued in 2026?
Based on GuruFocus' analysis, Globus Medical stock appears to be undervalued.
The current stock price of R$52.00 is trading 11.1% below its estimated GF Value™ of R$58.52.
GuruFocus considers Globus Medical to be Modestly Undervalued.
Key valuation signals for BSP:G2ME34:
EV-to-EBITDA: 0.91 (96% below median its 10-year median of 20.98)
GF Value™: R$58.52 vs. price of R$52.00 (11.1% below fair value)
Industry Position: 93.9% below the Medical Devices & Instruments median (#199 of 516)
No single metric tells the full story. See the BSP:G2ME34 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Globus Medical Inc is a medical device company that develops and provides healthcare products and solutions to hospitals, physicians, and surgical centers. The firm's products are organized into two categories: musculoskeletal solutions, which include medical devices and instruments used mostly for spinal and orthopedic procedures, and enabling technologies, which include computer systems developed for enhancing surgical capabilities. The vast majority of the company's revenue is generated from musculoskeletal solutions products, and more than half of the revenue is earned in the United States. It also has its presence internationally.
26GF Score
Get the complete analysis for BSP:G2ME34
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BSP:G2ME34 has been successfully added to your 
